Skip to Main Content

Economic Outcomes

March 17, 2023
Economic Outcomes
CGM Best Practices / Interview

Expert: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, Endocrine Clinical Pharmacy Specialist, Co-Director, Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute

Summary: Opportunities to improve care quality and reduce costly resource utilization in diverse patient populations with evidence-based utilization of CGM

October 12, 2022
Economic Outcomes
CGM Best Practices / Interview
Davida F Kruger

Expert: Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner at Henry Ford Health System (HFHS)/Health Alliance Plan (HAP)

Summary: HFHS/HAP’s experience in moving continuous glucose monitoring (CGM) from the durable medical equipment (DME) benefit to pharmacy coverage, demonstrating substantial cost savings at the plan level.

Short on time? Click here for an abbreviated version of this video interview.

July 11, 2022
Clinical Outcomes
Coverage and Benefit Design
Economic Outcomes
CE Activities

Intended Audience: Managed care pharmacists, health system pharmacists, and retail pharmacists

Time to Complete Activity: 3.0 hours


Click here to begin!

Educational Objectives
After completing this activity, the participant should be better able to:

  • Examine the guideline recommendations and recent data on the clinical benefits and optimal use of continuous glucose monitoring (CGM) for the management of diabetes.
  • Explore the social determinants of health that negatively affect patients with diabetes and strategies to promote health equity.
  • Investigate the value of CGM in optimizing the management of diabetes and opportunities to promote access to appropriate patients.

July 6, 2022
Coverage and Benefit Design
Economic Outcomes
Conference Updates

Key findings from the symposium at the Academy of Managed Care Pharmacy (AMCP) 2022 Annual Meeting.

Key Takeaways from Dr. Peek:
– rtCGM demonstrated a robust, sustained effect on glycemic control with fewer medications and no increase in insulin doses compared with
blood glucose monitoring (BGM) in the MOBILE RCT
– In the Kaiser analysis, rtCGM initiation reduced healthcare resource utilization for ER/admit due to hypoglycemia by 53%
– Expanded access to rtCGM is warranted based on these findings, particularly in underserved demographics disproportionately affected by

Key Takeaways from Dr. Mistry:
– Pharmacy coverage of rtCGM for members with T1 and T2D can result in reduced resource utilization from improvements in clinical
management as well as cost savings for health plans via administrative efficiencies

-rtCGM offers an opportunity for improved outcomes
and proven PMPM savings when covered under the pharmacy benefit

Key Takeaways from Kelly Close:
– CGM represents the single most important tool for improving clinical outcomes and quality of life for people with diabetes
– The lives of people with diabetes have improved exponentially over the past several decades, but continued advancement is possible
with increased access to CGM and the application of more sophisticated measures such as TIR

Jointly provided by Impact Education, LLC, and Medical Education Resources.
This activity is supported by an independent educational grant from Dexcom, Inc.

Learn More

  • 1-0 of 0 results